Dennis Carlo

Immune Response Corp. said that Dennis Carlo resigned as chief executive, and the company, which has struggled to develop an HIV treatment, is cutting more than half the staff at its headquarters in Carlsbad, Calif. Immune Response said it promoted its vice president for medical and scientific affairs, Ronald Moss, to president and is seeking a chief executive. Carlo will remain on the board of the company, which was co-founded by the late Jonas Salk, developer of the polio vaccine.

Immune Response Corp. said that Dennis Carlo resigned as chief executive, and the company, which has struggled to develop an HIV treatment, is cutting more than half the staff at its headquarters in Carlsbad, Calif. Immune Response said it promoted its vice president for medical and scientific affairs, Ronald Moss, to president and is seeking a chief executive. Carlo will remain on the board of the company, which was co-founded by the late Jonas Salk, developer of the polio vaccine.

* EchoStar Communications Corp. said its Dish Network satellite TV service will increase basic rates by $2 a month effective Feb. 1. The increase is to cover rising programming costs and the introduction of new channels, the company said. * A federal judge ruled that OpenTV Corp. may pursue patent infringement allegations against Liberate Technologies and said OpenTV didn't cause consumers to infringe a Liberate patent related to interactive television.

Immune Response Corp., the San Diego biotechnology company set up by Jonas Salk in 1986 to develop AIDS vaccines and treatments, has received a $15-million vote of confidence from a major U.S. pharmaceutical manufacturer. Rorer Group of Ft. Washington, Pa., said Thursday that it will buy 20% of IRC stock for $10 million and invest another $5 million in a joint venture between IRC and Rorer to research, develop and market AIDS-related products in the United States and Canada.

Immune Response Corp., the San Diego biotechnology company co-founded by Jonas Salk that is trying to develop an AIDS vaccine, has filed for permission to hold an 2.2-million share initial public stock offering that could raise as much as $19.8 million. The company is developing an immunotherapeutic drug for patients who have already contracted the HIV virus, the precursor to AIDS.

Immune Response Corp., the La Jolla pharmaceutical company co-founded by Jonas Salk that is trying to develop an AIDS vaccine, said Wednesday that it has signed a licensing deal with French vaccine manufacturer Pasteur Vaccins and its parent, Institut Merieux, that could be worth up to $7.5 million over the next three years. In addition, Immune Response Corp.

If a grand theme can be extracted from this year's survey of the county's highest paid public company executives, it may be that biotechnology has become an increasingly lucrative career. Although biotechnology companies represent just a small percentage of the county's publicly held companies, their executives have claims on a disproportionate share of the higher paying jobs.

Here are the highest-paid executives among San Diego County's publicly owned companies. Name Title Company 1 Robert E. Draper P National Health Labs 2 Thomas A. Page COB,P,CEO SDG&E 3 Thomas J. Wageman P, CEO HomeFed Corp 4 Arnold L. Johnson P,CEO Magma Power Co 5 R.H. Goldsmith COB,CEO Rohr Industries Inc 6 Bernard E. Statland VP National Health Labs 7 Walter J. Zable COB,P,CEO Cubic Corp 8 Jack E. Thomas EVP,COO SDG&E 9 John F. Markus VP National Health Labs 10 David C.

The complex entanglements between pharmaceutical companies and academic medical researchers have taken a bizarre twist in which a Carlsbad company is accusing UC San Francisco of suppressing favorable data about an anti-AIDS vaccine developed by the late Dr. Jonas Salk. Dr. James O. Kahn of UC San Francisco and his colleagues report in today's Journal of the American Medical Assn. that one of the largest AIDS trials ever, involving 2,527 patients at 77 U.S.

Oh, how he annoys them. "Salk?" they say, questioningly, derisively, with a roll of the eyeballs and clucking of the tongue and a stiffening of the back. "I'll tell you right off the bat," one declares bluntly. "I don't think Salk is a good scientist." Adds another: "He doesn't really understand what he's doing. He just forges ahead." Of course, this is not for publication. No, no, no. They mustn't be quoted. It would be unprofessional, untoward, to cast aspersions on a legend, although some do.